新抗原封存自细胞作为治疗性癌症疫苗
Jinxie Zhang1, Jiahui Cao1, Liuchang Wang1
1State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, PR China.
概括
一种基于自细胞的新型新抗原疫苗 (APNV) 与检查点阻塞疗法相结合,有望阻碍黑色素瘤复发和转移. 这种个性化癌症疫苗方法有效地激活免疫细胞,以加强免疫疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 新抗原是个性化癌症疫苗的理想目标,因为它们的免疫性和安全性.
- 现有的癌症免疫疗法可以通过新的疫苗输送系统来增强.
研究的目的:
- 开发和评估一种基因工程自细胞基的新抗原疫苗 (APNV),结合免疫检查点抑制剂用于癌症免疫疗法.
- 在临床前黑色素瘤模型中评估APNV的疗效.
主要方法:
- 工程NIH 3T3细胞共同表达黑色素瘤新抗原和LC3用于自细胞隔离.
- 新抗原自细胞被净化并用辅助剂 (HMGB1,GM-CSF) 配制成APNV水凝.
- 在体外和体内测试了APNV疗效,包括皮下黑色素瘤和肺转移模型,以及抗PD-1疗法.
主要成果:
- 在体外和体内,APNV成功地激活了树突细胞.
- 在黑色素瘤模型中,APNV和检查点阻塞疗法的结合显著减少了手术后瘤复发.
- 在黑色素瘤肺转移模型中,APNV治疗有效阻碍了转移性进展.
结论:
- 开发的基于自细胞的新抗原疫苗 (APNV) 在与检查点封锁相结合时表现出强大的抗瘤活性.
- APNV显示出作为癌症免疫治疗的个性化治疗疫苗的潜力,特别是黑色素瘤.
- 这种方法可以克服开发有效的基于新抗原的癌症疫苗的挑战.
相关概念视频
Tumor Immunotherapy
488
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
488
Cancer Vaccines
342
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
342
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K


